Latest Industry Insights

Dr. Adam Crowe sheds light on why a newly discovered reactive impurity is detrimental to mRNA function and how it can be detected more accurately.

To find out more about how generative artificial intelligence (AI) is helping to accelerate and advance drug discovery processes, we spoke to Dr. Alex Zhavoronkov, CEO of Insilico Medicine.

Dr. Mary McBride and Professor Chris Elliott, world-renowned for his work in food safety and authenticity, discuss his career to date, his passion for food safety, the projects his team are working on and the future.

To learn more about T-cell testing, the types of diseases it can help to diagnose and its value in clinical trials, we spoke to Phill Keefe, chief executive officer of PerkinElmer’s Oxford Immunotec division.

This article discusses how library-based approaches in quantitative proteomics can increase the sensitivity and accuracy of such detection systems.

To learn more about the Pioneer Antibody Discovery Platform and its potential impact on drug discovery and development, we spoke to Dr. John Cardone.

This article overviews the science behind the potential use of RRx-001as a “radiation buster” with anti-inflammatory and anti-free radical properties to prevent or reduce both GI-ARS and H-ARS.

We speak with Dr. Niall Martin, CEO of Artios Pharma, to learn more about the development of drugs to target the DNA damage response pathway in cancer.

In this opinion piece, Francois Rieger discusses why reverse mergers are the way forward for advanced therapies.

From increasing trial diversity to using plants to manufacture drugs, the experts weigh in.